| Property |
Value |
| Gene Symbol |
DNAJB5 |
| Full Name |
DnaJ Heat Shock Protein Family (Hsp40) Member B5 |
| Chr Location |
9p13.3 |
| NCBI Gene ID |
25822 |
| OMIM ID |
608591 |
| Ensembl ID |
ENSG00000135919 |
| UniProt ID |
O75164 |
| Encoded Protein |
DNAJB5 |
| Associated Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Cancer |
DNAJB5 (DnaJ Heat Shock Protein Family Member B5), also known as Hsp40 or DNAB5, is a member of the DnaJ/Hsp40 family of molecular chaperones. Located on chromosome 9p13.3, DNAJB5 functions as a co-chaperone that assists Hsp70 proteins in protein folding, refolding, and clearance of misfolded proteins [1][2].
The DNAJ/Hsp40 family is characterized by the presence of a highly conserved J-domain, which enables interaction with Hsp70 chaperones and stimulates their ATPase activity. This interaction is crucial for protein quality control mechanisms that prevent the accumulation of toxic protein aggregates—a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [2][3].
DNAJB5 has attracted attention for its potential role in preventing protein aggregation in neurodegenerative diseases, where it may help mitigate the accumulation of misfolded proteins such as amyloid-beta, tau, and alpha-synuclein [1][2].
¶ Molecular Structure and Biochemistry
DNAJB5 encodes a protein with distinct functional domains:
- J-Domain (1-70 aa): The defining feature of DNAJ proteins, containing the conserved HPD motif
- Gly/Phe-Rich Region (70-150 aa): Flexible linker region
- C-terminal Substrate-Binding Domain (150-320 aa): Binds client proteins for targeting to Hsp70
¶ The J-Domain Protein Family
DNAJB5 belongs to the DNAJ subfamily, which includes proteins with a full J-domain structure:
| Subfamily |
Characteristics |
Examples |
| DNAJA |
Contain J-domain + Gly/Phe-rich + C-terminal |
DNAJA1 (Hsp40), DNAJA2 |
| DNAJB |
Contain J-domain + variable C-terminal |
DNAJB5, DNAJB6, DNAJB8 |
| DNAJC |
Contain J-domain + additional domains |
DNAJC3, DNAJC13 |
DNAJB5 functions through:
- Hsp70 Recruitment: The J-domain recruits and activates Hsp70 proteins
- Substrate Targeting: The C-terminal domain binds misfolded proteins
- Handoff: Delivers substrates to Hsp70 for refolding or degradation
- Aggregate Disaggregation: Can work with Hsp70 and Hsp110 to dissolve aggregates
DNAJB5, in collaboration with Hsp70 family members, facilitates proper protein folding:
- Co-translational folding assistance
- Post-translational quality control
- Prevention of misfolding during stress
The DNAJB5-Hsp70 complex provides essential quality control functions [2][3]:
- Proteasomal Degradation: Targets ubiquitinated misfolded proteins for degradation
- Autophagic Clearance: Routes aggregates to autophagosomes
- Aggregate Disassembly: Works with disaggregases to reverse aggregation
DNAJB5 expression is regulated by cellular stress:
- Heat Shock Response: Upregulated under heat shock conditions
- Oxidative Stress: Induced by reactive oxygen species
- Proteotoxic Stress: Increased accumulation of misfolded proteins
DNAJB5 has been implicated in Alzheimer's disease pathogenesis through its role in protein quality control [1][2]:
- Amyloid-Beta Metabolism: May influence amyloid-beta production or clearance
- Tau Pathology: Potential involvement in tau aggregation and clearance
- Proteostasis Maintenance: Helps maintain neuronal proteostasis under stress
The accumulation of misfolded amyloid-beta and tau proteins is a hallmark of AD. DNAJB5 and other Hsp40 family members may provide protective functions by assisting in the clearance of these pathogenic proteins [2][3].
In Parkinson's disease, alpha-synuclein aggregation is a key pathological feature [1][2]. Research has shown that:
- DNAJ proteins can interact with alpha-synuclein
- Hsp40 overexpression reduces alpha-synuclein toxicity
- DNAJ family members influence aggregation kinetics
The study by Hasegawa et al. (2018) specifically addressed the DnaJ/Hsp40 family in Parkinson's disease, highlighting the importance of these chaperones in maintaining dopaminergic neuron health [1].
ALS is characterized by protein aggregation including TDP-43 and FUS [2][3]:
- DNAJB5 expression is altered in ALS models
- DNAJ proteins may help prevent toxic aggregation
- Chaperone dysfunction may contribute to disease progression
DNAJ proteins provide neuroprotection through multiple mechanisms [3][4]:
- Aggregate Prevention: Sequestration of aggregation-prone proteins
- Disaggregation: Working with Hsp110 and Hsp70 to dissolve aggregates
- Degradation Targeting: Directing misfolded proteins to the proteasome or autophagy
- Membrane Repair: Assisting in repair of damaged membranes
DNAJB5 represents a potential therapeutic target for neurodegenerative diseases [4]:
- Small Molecule Activators: Compounds that enhance DNAJB5 activity
- Gene Therapy: Viral delivery of DNAJB5 to neurons
- Protein-Based Therapies: Recombinant DNAJB5 administration
The development of engineered protein disaggregases based on Hsp40-Hsp70-Hsp110 complexes represents a promising therapeutic approach [4]. These designer disaggregases could potentially reverse protein aggregation in neurodegenerative diseases.
DNAJB5 exhibits broad tissue expression with notable brain localization:
- Highest Expression: Hippocampus, cerebral cortex, cerebellum
- Moderate Expression: Testis, ovary, heart
- Cellular Localization: Cytosolic and membrane-associated
Within the brain, DNAJB5 is expressed in:
- Hippocampal neurons (CA1-CA3 pyramidal cells)
- Cortical layer 2-4 neurons
- Cerebellar Purkinje cells
- Substantia nigra dopaminergic neurons
DNAJB5 expression is regulated by:
- Heat shock factor (HSF1)-dependent transcription
- Cellular stress conditions
- Developmental stage
DNAJB5 interacts with multiple Hsp70 family proteins [9][10]:
- HSPA1A (Hsp70-1): Major stress-inducible Hsp70
- HSPA8 (Hsc70): Constitutively expressed chaperone
- HSPA4 (Hsp110): Co-chaperone for disaggregation
- HSPA5 (BiP/Grp78): ER-resident chaperone
- HSPA9 (Mortalin): Mitochondrial Hsp70
DNAJB5 can also interface with Hsp90 chaperone system:
- Hsp90 client protein quality control
- Coordination between Hsp70 and Hsp90 systems
- Shared substrate targeting mechanisms
DNAJB5 may cooperate with other DNAJ family members [11]:
- DNAJB1 (Hsp40): Canonical Hsp40 co-chaperone
- DNAJB6: Brain-enriched Hsp40 with aggregation suppression
- DNAJB8: Testis-specific Hsp40
- DNAJC family members for broader proteostasis network
The aggregation of misfolded proteins follows a characteristic cascade [3][4][12]:
- Native State → Misfolding: Mutations, oxidative stress, or aging cause protein misfolding
- Oligomer Formation: Misfolded proteins form transient oligomers
- Nucleation: Oligomers serve as nuclei for further aggregation
- Fibril Extension: Ordered fibrils grow through template-assisted polymerization
- Amorphous Aggregation: Non-fibrillar aggregates accumulate
DNAJB5 intervenes at multiple points in this cascade:
- Prevents initial misfolding through folding assistance
- Captures early oligomers before they become nucleation-competent
- Routes aggregates to degradation pathways
- Works with disaggregases to reverse early fibril formation
DNAJB5 participates in multiple clearance pathways [13][14]:
Proteasomal Degradation (Ubiquitin-Proasome System):
- Recognizes ubiquitinated misfolded proteins
- Delivers substrates to the 26S proteasome
- Facilitates unfolding and translocation into the proteasome
- Works with Hsp70 to remove steric blocks
Autophagic Degradation:
- Chaperone-mediated autophagy (CMA): Direct delivery to lysosomes via LAMP-2A
- Macroautophagy: Bulk sequestration of aggregates into autophagosomes
- Endosomal microautophagy: Selective uptake at endosomal membranes
Alternative Pathways:
- Export to extracellular space
- Sequestration into aggresomes for controlled storage
¶ Membrane Protection and Repair
DNAJB5 contributes to membrane integrity [4]:
- Associates with damaged membranes
- Prevents aggregation of membrane-associated proteins
- Aids in membrane fusion/fission events
- Supports synaptic vesicle recycling
In Alzheimer's disease, DNAJB5 may modulate multiple pathological processes [1][2][15]:
Amyloid-Beta Metabolism:
- May influence APP processing and Aβ production
- Potential effects on α-secretase processing
- Clearance of Aβ aggregates through proteostasis
- Interaction with AChE and other Aβ-interacting proteins
Tau Pathology:
- Tau is an Hsp70 client protein
- DNAJB5 may assist in tau refolding/degradation
- Modulation of tau phosphorylation states
- Prevention of tau aggregate formation
Synaptic Proteostasis:
- Critical for synaptic protein quality control
- Supports AMPA receptor trafficking
- Maintains neurotransmitter release machinery
- Preserves synaptic plasticity under stress
Neuroinflammation Modulation:
- Modulates heat shock response in glia
- May regulate inflammatory cytokine expression
- Supports neuronal survival in inflammatory environments
In Parkinson's disease, alpha-synuclein aggregation is central [1][16]:
Alpha-Synuclein Homeostasis:
- DNAJ proteins including DNAJB5 interact with α-synuclein
- Prevents α-synuclein oligomerization
- May slow fibril extension kinetics
- Supports autophagic clearance of α-synuclein
Dopaminergic Neuron Vulnerability:
- High metabolic demand increases proteostatic stress
- Mitochondrial dysfunction amplifies protein damage
- DNAJB5 helps maintain proteostasis under these conditions
- May provide neuroprotection in SN neurons
LRRK2 Interaction:
- LRRK2 mutations are common in familial PD
- Hsp40 proteins may modulate LRRK2 aggregation
- Potential therapeutic modulation strategies
- Interaction with other PD-associated proteins
ALS features protein aggregation in motor neurons [2][3]:
TDP-43 Pathology:
- TDP-43 is a major aggregating protein in ALS
- DNAJ proteins may modulate TDP-43 aggregation
- Hsp40 family members show altered expression in ALS
- Potential for therapeutic intervention
FUS Proteinopathy:
- FUS is another aggregating protein in ALS
- Hsp40 proteins can interact with FUS
- DNAJB5 may modulate FUS aggregation
- Related to RNA processing dysfunction
C9orf72 Hexanucleotide Expansion:
- Most common genetic cause of ALS/FTD
- Produces toxic dipeptide repeats
- DNAJ proteins may counteract this toxicity
- Potential for modifier-based therapy
Huntington's disease involves mutant huntingtin aggregation [17][18]:
Huntingtin Quality Control:
- Mutant huntingtin has expanded polyglutamine tract
- DNAJB5 can triage mutant huntingtin aggregates
- Prevents toxic oligomer formation
- Routes to degradation pathways
Modulation of Aggregation Kinetics:
- Slows nucleation phase
- Reduces fibril growth rate
- Decreases overall aggregate burden
- Maintains proteostasis longer
Hsp70/Hsp40 Modulators:
- Agonists that enhance chaperone activity
- Compounds that increase DNAJB5 expression
- Allosteric activators of J-domain function
Disaggregation Enhancers:
- Support Hsp110-Hsp70-Hsp40 system
- Increase aggregate dissolution rates
- Synergy with autophagy induction
Viral Vector Delivery:
- AAV-mediated DNAJB5 overexpression
- Targeting specific brain regions
- Cell type-specific promoters
- Regulated expression systems
Gene Editing:
- Enhance endogenous DNAJB5 expression
- Modify regulatory elements
- Optimize codon usage for better translation
Recombinant Protein Delivery:
- Purified DNAJB5 protein administration
- Engineered variants with enhanced activity
- Cell-penetrating variants
- Targeted delivery to neurons
Peptide-Based Approaches:
- J-domain peptides for Hsp70 activation
- Substrate-binding domain fragments
- Cell-permeable chaperone mimetics
Chaperone + Degradation:
- Combine DNAJB5 enhancement with proteasome/ autophagy activators
- Coordinated clearance of existing aggregates
- Prevention of new aggregate formation
Chaperone + Anti-aggregation:
- Small molecule aggregation inhibitors
- Antibody-based approaches
- Multi-target combination therapy
- Co-immunoprecipitation: Identify DNAJB5 interacting partners
- Yeast two-hybrid screening: Map interaction domains
- Surface plasmon resonance: Measure binding affinities
- Fluorescence resonance energy transfer (FRET): Monitor complex formation in cells
- Thioflavin T fluorescence: Quantify fibril formation
- Electron microscopy: Visualize aggregate structures
- Atomic force microscopy: Measure aggregate morphology
- Sedimentation assays: Separate soluble from aggregated protein
- Neuronal cell lines: SH-SY5Y, PC12, N2a
- Primary neuron cultures: Mouse cortical neurons
- iPSC-derived neurons: Patient-specific models
- Organoid systems: Brain organoids for complex models
- Transgenic mice: Models of protein aggregation diseases
- Knockout mice: DNAJB5 loss-of-function studies
- Viral transduction: Local overexpression in brain
- Behavioral testing: Cognitive and motor assessments
DNAJB5 is evolutionarily conserved across eukaryotes:
| Species |
Homolog |
Conservation |
| Human |
DNAJB5 |
Reference |
| Mouse |
Dnajb5 |
Very high (95%+) |
| Zebrafish |
dnajb5 |
High |
| D. melanogaster |
dnaJ-1 |
Moderate |
| C. elegans |
dnj-10 |
Moderate |
| S. cerevisiae |
YDJ1 |
Lower |
Key functional domains are highly conserved:
- J-domain: Nearly identical across species
- Gly/Phe-rich region: Variable but present
- C-terminal domain: Moderately conserved
¶ Genetic Variations and Polymorphisms
DNAJB5 genetic variations have been studied:
- SNPs: Various single nucleotide polymorphisms identified
- Population frequency: Common variants in population databases
- Functional effects: Most variants have mild effects
- Disease associations: Limited direct evidence
Currently, DNAJB5 variants are not strongly associated with:
- Rare monogenic diseases
- Strong risk factors for complex diseases
- Pharmacogenomic considerations
However, DNAJB5 expression and common variants may modify:
- Neurodegenerative disease progression
- Response to chaperone-based therapies
- Protein aggregation disease severity
- In vivo function: Better understanding of DNAJB5 in living organisms
- Cell-type specificity: Which neurons benefit most from DNAJB5
- Aggregate specificity: Does DNAJB5 prefer specific aggregate types
- Therapeutic windows: Optimal timing for intervention
- Biomarkers: Surrogate markers for chaperone activity
- Cryo-EM structures: High-resolution chaperone-substrate complexes
- Single-molecule studies: Real-time observation of chaperone action
- Systems biology: Integration into cellular proteostasis networks
- Synthetic biology: Engineered chaperones with enhanced properties
- Clinical translation: Moving basic science to therapies
- Hasegawa et al., DnaJ/Hsp40 Family and Parkinson's Disease (2018)
- He & Wang, The roles of HSP40/DNAJ protein family in neurodegenerative diseases (2022)
- Zarouchlioti et al., DNAJ Proteins in neurodegeneration: essential and protective factors (2018)
- Shorter, Designer protein disaggregases to counter neurodegenerative disease (2017)
- Pang et al., Critical role of zebrafish dnajb5 in myocardial proliferation and regeneration (2020)
- Ago et al., A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy (2008)
- Lampis et al., MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma (2018)
- Schulze et al., Gene expression in IBD (2008)
- Kampinga et al., Guidelines for the nomenclature of the human heat shock proteins (2010)
- Chen et al., The HSP40 family in neurodegenerative diseases (2019)
- Chen et al., Autophagy-modulating proteins in neurodegeneration (2020)
- Jackson et al., Hsp40 proteins triage mutant huntingtin (2018)
- Goloubinoff et al., How do small heat shock proteins work? (2009)
- Liberek et al., The Hsp70/Hsp40 chaperone system (2008)
- Mayer et al., Hsp70 chaperone dynamics (2010)
- Vodermayer et al., Human Hsp40/DNAJ proteins in neurodegeneration (2009)
- Terryn et al., The role of DNAJB proteins in protein homeostasis (2018)